139 related articles for article (PubMed ID: 37956929)
1. Intranasal delivery of sunitinib: A new therapeutic approach for targeting angiogenesis of glioblastoma.
Seidkhani E; Moradi F; Rustamzadeh A; Simorgh S; Shirvalilou S; Mehdizadeh M; Dehghani H; Akbarnejad Z; Motevalian M; Gorgich EAC
Toxicol Appl Pharmacol; 2023 Dec; 481():116754. PubMed ID: 37956929
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
4. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma.
Costa PM; Cardoso AL; Nóbrega C; Pereira de Almeida LF; Bruce JN; Canoll P; Pedroso de Lima MC
Hum Mol Genet; 2013 Mar; 22(5):904-18. PubMed ID: 23201752
[TBL] [Abstract][Full Text] [Related]
6. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
7. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
van Linde ME; Labots M; Brahm CG; Hovinga KE; De Witt Hamer PC; Honeywell RJ; de Goeij-de Haas R; Henneman AA; Knol JC; Peters GJ; Dekker H; Piersma SR; Pham TV; Vandertop WP; Jiménez CR; Verheul HMW
Clin Cancer Res; 2022 Apr; 28(8):1595-1602. PubMed ID: 35165100
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
[TBL] [Abstract][Full Text] [Related]
10. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
Czabanka M; Vinci M; Heppner F; Ullrich A; Vajkoczy P
Int J Cancer; 2009 Mar; 124(6):1293-300. PubMed ID: 19101989
[TBL] [Abstract][Full Text] [Related]
11. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
[TBL] [Abstract][Full Text] [Related]
12. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
13. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
14. Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature.
Grisanti S; Ferrari VD; Buglione M; Agazzi GM; Liserre R; Poliani L; Buttolo L; Gipponi S; Pedersini R; Consoli F; Panciani P; Roca E; Spena G; Triggiani L; Berruti A;
J Neurosurg Sci; 2019 Aug; 63(4):458-467. PubMed ID: 27680966
[TBL] [Abstract][Full Text] [Related]
15. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive transferrin targeted nanovesicles sensitize resistant glioblastoma multiforme tumors and improve survival in orthotopic mouse models.
Sandbhor P; Goda J; Mohanty B; Chaudhari P; Dutt S; Banerjee R
Nanoscale; 2021 Dec; 14(1):108-126. PubMed ID: 34897360
[TBL] [Abstract][Full Text] [Related]
17. Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model.
Sandbhor P; Goda J; Mohanty B; Gera P; Yadav S; Chekuri G; Chaudhari P; Dutt S; Banerjee R
Drug Deliv Transl Res; 2023 Feb; 13(2):608-626. PubMed ID: 36245060
[TBL] [Abstract][Full Text] [Related]
18. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management.
Upadhaya PG; Pulakkat S; Patravale VB
Drug Deliv Transl Res; 2020 Aug; 10(4):1044-1056. PubMed ID: 32221847
[TBL] [Abstract][Full Text] [Related]
19. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]